Therapeutics To Collaborate On Developing Suppliers In Usa New York

LSI Solutions was founded in 1986 by our President & Chief Executive Officer, Jude S. Sauer, M.D., with a passion to focus on patient outcomes. What once started with a focus on laser tissue welding has evolved into a world renowned company ...

We develop and commercialize patented, disruptive liquid biopsy tests – innovative blood tests in oncology – based on a unique cell isolation technology called ISET (Isolation by SizE of Tumor cells) and cyto-molecular profiling of Circulating Tumor ...

Woolsey Pharmaceuticals is focused on the treatment of rare, neurodegenerative diseases. Many neurodegenerative diseases – including Alzheimer’s, vascular dementia, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, Huntington’s disease, ...

Oligomerix is a biotechnology company focused on developing disease-modifying and treatment therapeutics for neurodegenerative diseases characterized by aberrant tau protein ranging from rare tauopathies such as progressive supranuclear palsy ...

Beyond Air, Inc. is a clinical-stage medical device and biopharmaceutical company developing a revolutionary NO Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential ...

POP Biotechnologies, Inc. (POP BIO) is dedicated to addressing critical medical challenges with advanced nanotechnologies. POP BIO’s key breakthrough, the porphyrin-phospholipid (PoP) platform, facilitates the creation of powerful light-targeted ...

Founded by Flagship Pioneering, Valo is a mission-driven technology company that was created with the belief that the drug discovery and development process can and should be better—faster, less expensive, and with a higher probability of success. ...

We are a biopharmaceutical company developing transformational therapeutics targeting serious diseases with significant unmet medical needs. Our mission is to improve patient outcomes and save lives. To achieve our mission, we seek to capitalize on ...